AgriSURE Fund backs ELMED Life Sciences to drive innovation and growth in the biotech space.
ELMED Life Sciences has raised $2.7 million in a Series A round led by AgriSURE Fund, managed by NABVENTURES.
The funding marks a significant step for the Hyderabad-based startup as it expands its presence across multiple sectors, including agriculture, animal health, and human health.
Scaling Manufacturing and Research
The company plans to use the capital to expand its manufacturing capabilities in Hyderabad while strengthening research and development.
It will also focus on building distribution networks across Tier 2 and Tier 3 markets in India, alongside increasing its footprint in international markets.
This dual approach reflects a strategy aimed at both domestic penetration and global scale.
Building on Microbiome-Based Innovation
Founded in 2018 by Pruthivin Reddy Madduri and Nikhil Konkathi, ELMED Life Sciences develops probiotic and biological solutions powered by microbiome science.
Its products span poultry, dairy, livestock, aquaculture, and soil health, targeting productivity improvements while aligning with sustainability goals.
The company operates across a wide spectrum of use cases, positioning itself within the growing global shift toward biological alternatives in agriculture and healthcare.
A B2B Model with Enterprise Partnerships
ELMED follows a business-to-business model, supplying formulations to pharmaceutical and healthcare companies.
It works with partners such as Alchem, Hetero, Aurobindo, and Apex Laboratories, which market the final products under their own brands.
This model allows the company to scale production and distribution without building a consumer-facing brand, focusing instead on formulation and manufacturing expertise.
Expanding Global Reach
The startup currently exports to more than 18 countries and is targeting further expansion across Europe, Asia, and Latin America.
International growth is expected to play a key role in its next phase, particularly as demand rises for sustainable and residue-free biological solutions.
Investor Focus on Sustainable Agriculture
Ashish Choudhary highlighted the increasing demand for biological inputs as agriculture shifts toward sustainability.
The investment aligns with a broader trend of supporting solutions that reduce chemical dependence while improving productivity and efficiency across food systems.
Positioning for the Next Growth Phase
ELMED Life Sciences is operating at the intersection of biotechnology, agriculture, and healthcare, sectors that are increasingly converging through advances in microbiome research.
With fresh capital, expanded manufacturing, and growing global demand, the company is positioning itself as a scalable player in the biological solutions space, where science-driven innovation is beginning to reshape traditional industries.
